CA2568673A1 - Pyridine analogs as c5a antagonists - Google Patents

Pyridine analogs as c5a antagonists Download PDF

Info

Publication number
CA2568673A1
CA2568673A1 CA002568673A CA2568673A CA2568673A1 CA 2568673 A1 CA2568673 A1 CA 2568673A1 CA 002568673 A CA002568673 A CA 002568673A CA 2568673 A CA2568673 A CA 2568673A CA 2568673 A1 CA2568673 A1 CA 2568673A1
Authority
CA
Canada
Prior art keywords
6alkyl
tetrahydroquinoline
isopropylphenyl
carboxamide
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002568673A
Other languages
English (en)
French (fr)
Inventor
Nicolas Lachance
Yves Leblanc
Patrick Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2568673A1 publication Critical patent/CA2568673A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CA002568673A 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists Abandoned CA2568673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57850004P 2004-06-10 2004-06-10
US60/578,500 2004-06-10
PCT/CA2005/000891 WO2005121095A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists

Publications (1)

Publication Number Publication Date
CA2568673A1 true CA2568673A1 (en) 2005-12-22

Family

ID=35502992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002568673A Abandoned CA2568673A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists

Country Status (7)

Country Link
US (2) US7429666B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758865A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008501722A (cg-RX-API-DMAC7.html)
CN (1) CN1968931A (cg-RX-API-DMAC7.html)
AU (1) AU2005251839A1 (cg-RX-API-DMAC7.html)
CA (1) CA2568673A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005121095A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
NZ570844A (en) * 2006-02-28 2011-11-25 Helicon Therapeutics Inc Therapeutic piperazines as PDE4 inhibitors
CN101553244B (zh) * 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
KR20090074219A (ko) * 2006-10-04 2009-07-06 쉐링 코포레이션 트롬빈 수용체 길항제로서의 비사이클릭 및 트리사이클릭 유도체
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
CN108508130B (zh) * 2018-04-11 2020-01-17 国家烟草质量监督检验中心 一种超高效合相色谱-串联质谱技术拆分、测定手性农药甲霜灵和烯酰吗啉对映体的方法
US20240293380A1 (en) * 2021-06-16 2024-09-05 The Cleveland Clinic Foundation Protease inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
CA2479930A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
US20040014782A1 (en) * 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists

Also Published As

Publication number Publication date
EP1758865A1 (en) 2007-03-07
WO2005121095A1 (en) 2005-12-22
US20050277644A1 (en) 2005-12-15
CN1968931A (zh) 2007-05-23
EP1758865A4 (en) 2010-07-21
JP2008501722A (ja) 2008-01-24
US20090023774A1 (en) 2009-01-22
US7429666B2 (en) 2008-09-30
AU2005251839A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
US20090023774A1 (en) Pyridine analogs as C5A antagonists
KR102408261B1 (ko) Ror-감마의 디하이드로피롤로피리딘 저해제
JP6914257B2 (ja) Ｒｏｒ−ガンマのモジュレーター
AU2018278311B2 (en) IRE1 small molecule inhibitors
TWI282335B (en) A61k 31/437 200601 a i vhtw a61p 31/04 200601 a i vhtw
RU2734760C2 (ru) Противоинфекционные соединения
DE69925150T2 (de) Naphthyridin-Verbindungen und ihre Azaisosteren Analoga als antibakterielle Mittel
DE69928952T2 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
KR20220092920A (ko) 헬리오스의 소분자 분해제 및 사용 방법
Domagala et al. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1-pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy
KR20190140931A (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
JP2011526295A (ja) ５員および６員複素環化合物
US20080234318A1 (en) Chemical Compounds
JPS61243077A (ja) 抗菌剤
JP2000501432A (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
TW202302583A (zh) Ｔｙｋ２抑制劑及其用途
US20100137276A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
JP2021529161A (ja) ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール
TW202404969A (zh) 用於治療疼痛之雜芳基化合物
KR100231095B1 (ko) 피리다진디온 화합물
US20250049814A1 (en) 5-azaindazole derivatives as adenosine receptor antagonists
ES2872005T3 (es) Sulfonas heterocíclicas como moduladores de ROR gamma
AU2011336217B2 (en) KAT II inhibitors
JP7561285B2 (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
CA3207475A1 (en) Quinoxaline derivatives and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued